Literature DB >> 10938436

Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons.

M Lesort1, G V Johnson.   

Abstract

The modulation of tau phosphorylation and localization in response to insulin-like growth factor-1 or insulin was examined in primary cultures of rat cortical neurons. Insulin and insulin-like growth factor-1 treatment resulted in a rapid and transient increase in tau phosphorylation at specific epitopes. These effects were completely inhibited by lithium, revealing that the insulin and insulin-like growth factor-1 induced changes in tau phosphorylation were mediated by glycogen synthase kinase-3beta. In addition, the increase in tau phosphorylation directly correlated with a transient dissociation of tau from the cytoskeleton, indicating that insulin and insulin-like growth factor-1 treatment resulted in a change in tau localization. Using immunocytochemistry, it was also demonstrated that treatment of neurons with insulin-like growth factor-1 for 3 min resulted in a redistribution of tau to the growth cone and the distal segment of the axons. Further, insulin-like growth factor-1 treatment resulted in an increased immunoreactivity with the phospho-dependent antibody AT8 in the same areas of the axons. Thus, the phosphorylation state and distribution of tau can be modulated by insulin and insulin-like growth factor-1 signaling pathways involving glycogen synthase kinase-3beta. We propose that by transiently increasing tau phosphorylation, insulin and insulin-like growth factor-1 may contribute to the reorganization of the cytoskeleton necessary for the development and growth of the neurites.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938436     DOI: 10.1016/s0306-4522(00)00200-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  36 in total

1.  Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

Authors:  L Gasparini; G K Gouras; R Wang; R S Gross; M F Beal; P Greengard; H Xu
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 2.  Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit?

Authors:  Luigi Puglielli
Journal:  Neurobiol Aging       Date:  2007-02-20       Impact factor: 4.673

3.  T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-beta peptide.

Authors:  Tatsuo Kimura; Phuong Thi Hong Nguyen; Son Anh Ho; Anh Hai Tran; Taketoshi Ono; Hisao Nishijo
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 4.  The association of diabetes and dementia and possible implications for nondiabetic populations.

Authors:  Ramit Ravona-Springer; Michal Schnaider-Beeri
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

Review 5.  Biomarkers in Alzheimer's disease: past, present and future.

Authors:  Katarzyna Gustaw-Rothenberg; Alan Lerner; David J Bonda; Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 6.  Deregulation of brain insulin signaling in Alzheimer's disease.

Authors:  Yanxing Chen; Yanqiu Deng; Baorong Zhang; Cheng-Xin Gong
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

7.  Cardiovascular dementia - a different perspective.

Authors:  Udhaya Kumari; Klaus Heese
Journal:  Open Biochem J       Date:  2010-03-26

8.  Presenilin-1 regulates induction of hypoxia inducible factor-1α: altered activation by a mutation associated with familial Alzheimer's disease.

Authors:  Rita De Gasperi; Miguel A Gama Sosa; Stella Dracheva; Gregory A Elder
Journal:  Mol Neurodegener       Date:  2010-09-23       Impact factor: 14.195

9.  Contribution of vascular risk factors to the progression in Alzheimer disease.

Authors:  Elizabeth P Helzner; José A Luchsinger; Nikolaos Scarmeas; Stephanie Cosentino; Adam M Brickman; M Maria Glymour; Yaakov Stern
Journal:  Arch Neurol       Date:  2009-03

10.  Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice.

Authors:  Richard Killick; Georgie Scales; Karelle Leroy; Mirsada Causevic; Claudie Hooper; Elaine E Irvine; Agharul I Choudhury; Laura Drinkwater; Fiona Kerr; Hind Al-Qassab; John Stephenson; Zehra Yilmaz; K Peter Giese; Jean-Pierre Brion; Dominic J Withers; Simon Lovestone
Journal:  Biochem Biophys Res Commun       Date:  2009-06-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.